BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17805550)

  • 1. Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer.
    de Oca J; Azuara D; Sanchez-Santos R; Navarro M; Capella G; Moreno V; Sola A; Hotter G; Biondo S; Osorio A; Martí-Ragué J; Rafecas A
    Int J Colorectal Dis; 2008 Jan; 23(1):21-7. PubMed ID: 17805550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
    Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
    Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.
    Takahashi T; Kato T; Kodaira S; Koyama Y; Sakabe T; Tominaga T; Hamano K; Yasutomi M; Ogawa N
    Am J Clin Oncol; 1996 Aug; 19(4):408-15. PubMed ID: 8677916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of Src activation in stage II-III colon cancer.
    Martínez-Pérez J; Lopez-Calderero I; Saez C; Benavent M; Limon ML; Gonzalez-Exposito R; Soldevilla B; Riesco-Martínez MC; Salamanca J; Carnero A; Garcia-Carbonero R
    Hum Pathol; 2017 Sep; 67():119-125. PubMed ID: 28601656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
    Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
    Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of prognostic factors after radical resection in 628 patients with stage II or III colon cancer].
    Qin Q; Yang L; Zhou AP; Sun YK; Song Y; DU F; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):212-6. PubMed ID: 23880003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.
    Cienfuegos JA; Martínez P; Baixauli J; Beorlegui C; Rosenstone S; Sola JJ; Rodríguez J; Hernández-Lizoáin JL
    Ann Surg Oncol; 2017 Apr; 24(4):1077-1084. PubMed ID: 27624582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer.
    Cakar B; Varol U; Junushova B; Muslu U; Gursoy Oner P; Gokhan Surmeli Z; Cirak Y; Karaca B; Sezgin C; Karabulut B; Uslu R
    J BUON; 2013; 18(2):372-6. PubMed ID: 23818348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
    Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
    Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.